The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Lipase Inhibitors for Obesity: A Review
Open accessAbstract
With the rapid increase in the population of obese individuals, obesity has become a global problem. Many kinds of chronic metabolic diseases easily caused by obesity have received increasing attention from researchers. People are also striving to find various safe and effective treatment methods as well as anti-obesity medicines. Pancreatic lipase (PL) inhibitors have received substantial attention from researchers in recent years, and PL inhibitors from natural products have attracted much attention due to their structural diversity, low toxicity and wide range of sources. They have been used in the intestinal tract, blood, and the central nervous system with no side effects, and these advantages could lead to a new generation of diet pills or health care products with great development potential. This article is mainly aimed at discussing the research of obesity drug treatment with PL inhibitors and offers a brief review of related properties and the use of PL inhibitors in the field of weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ferreira, D. M. S., Castro, R. E., Machado, M. V., Evangelista, T., Silvestre, A. R., Costa, A., Coutinho, J. R. H., Carepa, F., Cortez‐Pinto, H., & Rodrigues, C. M. P. (2011) · Diabetologia · doi:10.1007/s00125-011-2130-8 · Cited by 103
RetractedNonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats
Johnson, P. M., & Kenny, P. J. (2010) · Nature Neuroscience · doi:10.1038/nn.2519 · Cited by 1,495
Structure of human pancreatic lipase
Winkler, F. K., D'Arcy, A., & Hunziker, W. (1990) · Nature · doi:10.1038/343771a0 · Cited by 1,224
Pancreatic lipase inhibitors from natural sources: Unexplored potential
Birari, R. B., & Bhutani, K. K. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.024 · Cited by 871
Lowering blood cholesterol to prevent heart disease
Hupp, J. R. (1985) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/0278-2391(85)90208-3 · Cited by 644
Orlistat, a New Lipase Inhibitor for the Management of Obesity
Heck, A. M., Yanovski, J. A., & Calis, K. A. (2000) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.4.270.34882 · Cited by 572
Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404
Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes
Bjerregaard, L. G., Jensen, B. W., Ängquist, L., Osler, M., Sørensen, T. I. A., & Baker, J. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713231 · Cited by 392
Cited by
Shaik Mohamed Sayed, U. F., Moshawih, S., Goh, H. P., Kifli, N., Gupta, G., Singh, S. K., Chellappan, D. K., Dua, K., Hermansyah, A., Ser, H. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182937 · Cited by 136
Ishibashi, T., Tanioka, H., Ikehara, T., Kezbor, S., & Sonoyama, T. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-024-01418-3 · Cited by 4
Metadata
- Authors
- Liu, T.-T., Liu, X.-T., Chen, Q.-X., & Shi, Y.
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 128
- Pages
- 110314
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W3029948906
- Cited by
- 403
- References
- 69
- FWCI
- 25.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipase Inhibitors for Obesity: A Review. https://app.cochat.ai/papers/10.1016/j.biopha.2020.110314
- The paper
- Liu, T.-T., Liu, X.-T., Chen, Q.-X., & Shi, Y. (2020). Lipase Inhibitors for Obesity: A Review. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2020.110314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
